We’re moving towards the ‘disease control’ phase of our response to COVID, which means learning to live with the virus. But significant challenges remain as authorities battle COVID fatigue.
Rigor acadêmico, estilo jornalístico
Todos os artigos de Pandemic
Exibindo 161 - 180 de 1583 artigos
A new review study has sought to understand the impact of the COVID pandemic on children’s school attainment.
Innovations in food science and technology are well-positioned to address many existing food systems challenges.
There have been concerns that lunar new year may cause the current wave of COVID infections in China to spread much further and faster. But the worst has likely passed.
How The Last of Us bucked the trend for failed video game adaptations and instead added depth to a much beloved game.
Clinically vulnerable people tended not to respond as well after the first and second shots, but their immunity rises to greater levels with a booster.
Fungal infections are quickly becoming a global concern.
Nearly all the wastewater samples from aircraft arriving in the UK showed evidence of COVID-infected passengers on board.
The repeated lesson from other countries is that the loss of immunity and the appearance of new variants make herd immunity a futile goal when it comes to COVID.
A couple of theories are popular for explaining why we’re currently seeing very high levels of respiratory viruses, but they’re not based in science.
An upgraded global response to future potential pandemic threats would give the best chance of eliminating new infectious diseases at source before they spread globally.
However, there are still challenges for fathers taking on equal or primary care responsibilities.
The XBB.1.5 subvariant — nicknamed ‘Kraken’ — is arguably the most genetically rich and most transmissible SARS-CoV-2 Omicron subvariant yet.
Suspended MP Andrew Bridgen’s comments are a prime example.
XBB.1.5, or ‘kraken’, can evade our immune systems better than earlier variants, and appears to be more infectious. But it’s not cause for alarm.
Data suggests the bivalent boosters are working well against omicron.
Companies around the world are rapidly reshoring factories, investing in new technologies and building their inventories – shifts that all mean higher costs for consumers.
Deep-seated structural issues in the NHS affect all patients, however they particularly impact people with long COVID who are trying to both understand a complex new illness and access healthcare.
China pursued COVID zero for too long and is now paying the price. But the rest of the world doesn’t have too much to worry about.
After a year of omicron variants, will we ever see a new variant of concern?
Principais colaboradores
-
Associate Professor, Epidemiology, Deakin University
-
Professor of Medicine, University of Virginia
-
Lecturer in Psychology, Swansea University
-
Joel Lexchin é um amigo do The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW Sydney
-
Professor, Biology, York University, Canada
-
Associate Professor of Viral Immunology, Department of Pathobiology, University of Guelph
-
Professor of Immunology and Associate Dean, Research and Graduate Studies, University of Guelph
-
Professor of Epidemiology Healthcare Infection and Infectious Diseases Control, UNSW Sydney
-
Dean and Professor of Public Health, The Ohio State University
-
Professor and Chair, Department of Journalism, Stellenbosch University
-
Bernard T. Ferrari Professor of Business, Johns Hopkins University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Medicine, Epidemiologist, Physician, McMaster University
-
Professor of Medicine, University of East Anglia
